Publicaciones en las que colabora con Maria Auxiliadora Dea Ayuela (13)

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46

2012

  1. Multilocus genotyping of Giardia duodenalis in lambs from Spain reveals a high heterogeneity

    Research in Veterinary Science, Vol. 93, Núm. 2, pp. 836-842

2011

  1. MIND-BEST: Web server for drugs and target discovery; Design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from trichomonas gallinae

    Journal of Proteome Research, Vol. 10, Núm. 4, pp. 1698-1718

  2. NL MIND-BEST: A web server for ligands and proteins discovery-Theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum

    Journal of Theoretical Biology, Vol. 276, Núm. 1, pp. 229-249

2009

  1. Occurrence and genotypes of Giardia isolated from lambs in Spain

    Parasitology International, Vol. 58, Núm. 3, pp. 297-299

2008

  1. HPLC assay for determination of amphotericin B in biological samples

    Biomedical Chromatography, Vol. 22, Núm. 4, pp. 402-407

2007

  1. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum

    International Journal of Antimicrobial Agents, Vol. 30, Núm. 4, pp. 325-329

  2. Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for In Vivo testing of antileishmanial compounds

    Veterinary Research Communications, Vol. 31, Núm. 6, pp. 703-717

2006

  1. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation

    Antimicrobial Agents and Chemotherapy, Vol. 50, Núm. 4, pp. 1195-1201

2005

  1. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B

    Journal of Drug Targeting, Vol. 13, Núm. 4, pp. 225-233

2004

  1. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis

    Journal of Drug Targeting, Vol. 12, Núm. 7, pp. 453-460

  2. Anti-leishmanial activity of a new formulation of amphotericin B

    Tropical Medicine and International Health, Vol. 9, Núm. 9, pp. 981-990

  3. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres

    Antimicrobial Agents and Chemotherapy, Vol. 48, Núm. 9, pp. 3246-3252